Canadian Rx-to-OTC switches
This article was originally published in The Tan Sheet
Executive Summary
Special Committee of Council approves three switches: nicotine transdermal patches (22 mg/day and less), effective June 1; nizatidine (75 mg), effective immediately; and sodium cromoglycate (2% nasal solution), effective June 15. Eli Lilly Canada has rights to a 100 mg and 300 mg Rx nizatidine. Health Canada does not release the names of companies that apply for switches. The deregulatory amendments will be published in the Canada Gazette Part II May 27...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning